Paragon Care Ltd Asset Resilience Ratio
Paragon Care Ltd asset resilience ratio. Paragon Care Ltd (PGC) has an Asset Resilience Ratio of 0.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PGC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Paragon Care Ltd (2000–2024)
Asset resilience ratio of Paragon Care Ltd from 2000 to 2024. This chart shows how Paragon Care Ltd's Asset Resilience Ratio has changed over time. Read PGC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Paragon Care Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Paragon Care Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Paragon Care Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Paragon Care Ltd Industry Peers by Asset Resilience Ratio
Compare Paragon Care Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SINOPHARM GROUP 1/5/O.N.
F:X2S1 |
Medical Distribution | 0.00% |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC |
Medical Distribution | 7.12% |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368 |
Medical Distribution | 1.77% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 3.91% |
Paragon Care Ltd Asset Resilience Ratio by Year (2000–2024)
Paragon Care Ltd asset resilience ratio by year from 2000 to 2024. The table below shows the annual Asset Resilience Ratio data for Paragon Care Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.06% | AU$719.00K ≈ $508.74K |
AU$1.13 Billion ≈ $800.18 Million |
-- |
| 2020-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$292.17 Million ≈ $206.73 Million |
-- |
| 2019-06-30 | 0.01% | AU$22.00K ≈ $15.57K |
AU$384.20 Million ≈ $271.84 Million |
0.00pp |
| 2018-06-30 | 0.01% | AU$21.00K ≈ $14.86K |
AU$349.75 Million ≈ $247.47 Million |
-11.17pp |
| 2017-06-30 | 11.17% | AU$18.56 Million ≈ $13.13 Million |
AU$166.05 Million ≈ $117.49 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$147.79 Million ≈ $104.57 Million |
-- |
| 2015-06-30 | 0.65% | AU$264.06K ≈ $186.84K |
AU$40.59 Million ≈ $28.72 Million |
-0.13pp |
| 2013-06-30 | 0.78% | AU$142.80K ≈ $101.04K |
AU$18.39 Million ≈ $13.01 Million |
+0.56pp |
| 2010-06-30 | 0.22% | AU$26.11K ≈ $18.48K |
AU$11.80 Million ≈ $8.35 Million |
-41.01pp |
| 2009-06-30 | 41.24% | AU$1.63 Million ≈ $1.16 Million |
AU$3.96 Million ≈ $2.80 Million |
+40.20pp |
| 2008-06-30 | 1.03% | AU$13.88K ≈ $9.82K |
AU$1.34 Million ≈ $950.81K |
-1.09pp |
| 2001-06-30 | 2.12% | AU$225.00K ≈ $159.20K |
AU$10.59 Million ≈ $7.50 Million |
-12.44pp |
| 2000-06-30 | 14.56% | AU$911.99K ≈ $645.29K |
AU$6.26 Million ≈ $4.43 Million |
-- |
About Paragon Care Ltd
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more